TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05625945

Intervention type: BEHAVIORAL
Intervention: Physical activity monitoring
Description: Physical activity patterns will be measured using the activPAL3 micro monitor

Intervention type: BEHAVIORAL
Intervention: Physical activity monitoring
Description: Physical activity patterns will be measured using the activPAL3 micro monitor
Study: NCT05631691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support for Students exposed to Trauma Program
Description: Support for students exposed to trauma program (SSET) is a school-based intervention program for students who have been exposed to traumatic events and exhibit signs of post-traumatic stress disorder (PTSD). (Jaycox, Langley, \& Dean, 2009; Jaycox, Langley, Stein et al., 2009). SSET is specifically designed for school teachers, school counsellors, and other non-clinical staff. SSET program is a series of 10 structured lessons designed to reduce post-traumatic and depressive symptoms and improve functioning in school children exposed to traumatic events. it includes psycho-education, relaxation, cognitive restructuring, social problems solving and behavioral exposure.
Study: NCT06133114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: 0.5 mg twice a day (1 mg a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: 0.5 mg twice a day (1 mg a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: 0.5 mg twice a day (1 mg a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5 mg once a day of Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5 mg once a day of Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 2 mg once a day of Buprenorphine
Study: NCT05809349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
Study: NCT05204641

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transfer provided by Human Biome Institute
Description: Fecal Microbiota Transfer with colonoscopy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transfer provided by Human Biome Institute
Description: Fecal Microbiota Transfer with colonoscopy
Study: NCT05905419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Phase
Description: Opioid-taking patients are assigned to take their prescribed opioid medication before (peak opioid phase) during 1 scan and after (trough opioid phase) during the other MRI scan
Study: NCT04919174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Sedation with remimazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Sedation with dexmedetomidine
Study: NCT04141020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microsurgical clipping
Description: Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
Study: NCT06414681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
Study: NCT05439525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan technique
Description: The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
Study: NCT06068829

Intervention type: DRUG
Intervention: Inebilizumab
Description: Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.

Intervention type: DRUG
Intervention: Rituximab(RTX)
Description: RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.
Study: NCT06356844

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resolvin supplement
Description: Transforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively.
Study: NCT05988970

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples will be collected at two times before the treatment initiation:
Description: * at 4:00 a.m.~* at 10:00 a.m.~Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable).
Study: NCT05177731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine for Injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally by mouth
Study: NCT04956978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Support Tool
Description: Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
Study: NCT03116490

Intervention type: PROCEDURE
Intervention: Anesthesia type
Description: RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .

Intervention type: PROCEDURE
Intervention: Anesthesia type
Description: RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
Study: NCT04432532

Intervention type: OTHER
Intervention: No intervention
Description: There are no interventions

Intervention type: OTHER
Intervention: No intervention
Description: There are no interventions
Study: NCT05375435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple therapy
Description: high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dual-therapy
Description: high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
Study: NCT06199661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APEX
Description: Three phases: warm-up, high-intensity interval training (HIIT) phase, cool-down. A 10-minute warm-up included deep breathing meditation and dynamic joint mobility exercises. Then, a 40-minute strength and balance workout in HIIT format with five different high-intensity (HI) exercises interspersed with five different postural stability recovery exercises. The HI intervals focused on enhancing cardiovascular fitness, muscle strength, and motor performance. The recovery intervals incorporated balance and mobility exercises. The HI exercises lasted 30 seconds for the first three weeks and then increased to 45 seconds in the fourth week while the recovery exercises lasted 60 seconds throughout the entire intervention. The HIIT phase was repeated three times in the 40 minute block. Lastly, a 10-minute cooldown consisting of standing and seated exercises similar to the warm-up.
Study: NCT05291221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intratracheal saline
Description: At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intratracheal Dexmedetomidine
Description: At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intratracheal Lidocaine
Description: At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
Study: NCT04707690

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraurethral laser therapy
Description: The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intraurethral SHAM laser therapy
Description: The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
Study: NCT04795817

Intervention type: DEVICE
Intervention: Transoral Robotic Surgery
Description: Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
Study: NCT05439525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: 1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: 1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness
Study: NCT06285227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313
Study: NCT05208619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anaesthesia
Description: Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anaesthesia
Description: Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
Study: NCT04446780

Intervention type: PROCEDURE
Intervention: Mediolateral episiotomy
Description: Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
Study: NCT06111144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polarized training intensity distribution (TID) and mental training using mindfulness
Description: Polarized TID model group with mindfulness program (POL+)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pyramidal training intensity distribution (TID) and mental training using mindfulness
Description: Pyramidal TID model group with mindfulness program (PYR+)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polarized training intensity distribution (TID) without mindfulness
Description: Polarized TID model group without mindfulness program (POL-)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pyramidal training intensity distribution (TID) without mindfulness
Description: Pyramidal TID model group without mindfulness program (PYR-).
Study: NCT05763394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polarized workout program
Description: Polarized workout lasting approximately 40 minutes (two sessions/day, 5 days a week), characterized by a 5-minute warm-up performed at 50% of the peak V'O2, followed by 3 sets of 2 minutes at 95% of peak V'O2, interspersed with 1 minute of recovery at 40% of peak V'O2, followed by 30 minutes of moderate activity at 60% of V'O2 peak. Total of 24 sessions in 12 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity workout program
Description: High intensity workout (HIIT) (two sessions/day, 5 days a week), characterized by a 10-minute warm-up performed at 50% of peak V'O2 , followed by 6 series of 40 s of high-intensity walking corresponding to 95% of peak V'O2, interspersed with 5 minutes of walking at 40% of peak V'O2, ending with 5' of cool-down at 50% of the peak V'O2. Total of 24 sessions in 12 days.
Study: NCT05115214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpherePVI™ Catheter
Description: Affera SpherePVI™ Multi-Ablation System
Study: NCT05685264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponsegromab
Description: Participants will receive one subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponsegromab
Description: Participants will receive four subcutaneous injections
Study: NCT05195047

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 week placebo(Week 1)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 1)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 1)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week of probiotics(Week 1)
Description: 1 week of consecutively consuming oral probiotics (1 time/day)
Study: NCT06525558

Intervention type: PROCEDURE
Intervention: Intestinal resection
Description: This study does not add additional risks for patients as the resected specimen is collected during the surgery in accordance with standard clinical practice.

Intervention type: PROCEDURE
Intervention: Intestinal resection
Description: This study does not add additional risks for patients as the resected specimen is collected during the surgery in accordance with standard clinical practice.
Study: NCT05902221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin or moxifloxacin
Description: Antibiotic treatment back bone during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin or moxifloxacin + rifampicin
Description: Antibiotic treatment back bone during 12 weeks + rifampicin
Study: NCT05240378

Intervention type: OTHER
Intervention: Surgery
Description: Surgery for cancer as per the stage of the disease and protocol

Intervention type: OTHER
Intervention: Surgery
Description: Surgery for cancer as per the stage of the disease and protocol
Study: NCT05738460

Intervention type: DRUG
Intervention: antibiotics
Description: Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
Study: NCT05598177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will pump saline without dexmedetomidine at the same speed as group D.
Study: NCT05334927

Intervention type: BEHAVIORAL
Intervention: Medicine Overuse Headache/New Daily Persistent Headache
Description: At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.

Intervention type: BEHAVIORAL
Intervention: Chronic Migraine
Description: long-term follow-up

Intervention type: BEHAVIORAL
Intervention: Patients with other types of primary headache
Description: No collection Brain imaging、Cognitive function test、Biological sample
Study: NCT05195047

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 week placebo(Week 2)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 2)
Description: 1 week of consecutively consuming oral placebo (1 time/day)
Study: NCT05373134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
Study: NCT05195047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 2)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week of probiotics(Week 2)
Description: 1 week of consecutively consuming oral probiotics (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 week placebo(Week 3)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 3)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 3)
Description: 1 week of consecutively consuming oral placebo (1 time/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week of probiotics(Week 3)
Description: 1 week of consecutively consuming oral probiotics (1 time/day)
Study: NCT05373134

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04930770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRNA-1273
Description: Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
Study: NCT04779905

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary albumbin/creatinine ratio
Description: detection of microalbuminuria in nafld patients

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary albumbin/creatinine ratio
Description: detection of microalbuminuria in nafld patients
Study: NCT05660954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: * All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.~* Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose.
Study: NCT05315661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-STEM
Description: mesenchymal stem cells preconditioned with ethionamide
Study: NCT04707911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Description: Social media based intervention using Instagram with up to 3 posts per day for 30 days
Study: NCT05185596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography
Description: transesophageal Echocardiography during advanced life support
Study: NCT06336980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing Inclusionary Practices in Faith Communities
Description: Congregational inclusion committees will participate in monthly training meetings for approximately 1 year. Each month a new inclusion practice will be introduced and then the committee will be asked to implement it in their congregation. The 11 practice areas are:1) assessing inclusion needs of members, 2) providing opportunities for members with serious mental illness (SMI) to take on roles and responsibilities, 3) creating an inclusion committee, 4) ensuring that members with SMI are welcomed to all events, 5) creating sensory friendly spaces, 6) offer participation opportunities in multiple formats, 7) adopt policies and practices to support inclusion, 8) using inclusive language, 9) ensure that external communications indicate the congregation is welcoming to all, 10) providing support to family members of individuals with SMI, and 11) conducing outreach to mental health support systems. Goals may vary per congregation based on their current practices, needs, and preferences.
Study: NCT05358587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided PENG block with 20 mL Local Anesthetic solution
Description: In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided PENG block with 30 mL Local Anesthetic solution
Description: In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.